Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02769000 : Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's
PhasePhase 2
AgesMin: 55 Years Max: N/A
Eligibility
Inclusion Criteria:

- Must be a native English speaker with a LAR available for consenting.

- Able to complete neurocognitive function assessments, psychological function
assessments, and QOL assessments administered at screening visit.

- Rosen Modified Hachinski Ischemic Score less than or equal to 4

- Estimated Survival of greater than 12 months

- Meets the clinical definition of AD based on NINCDS-ADRDA criteria, with confirmatory
F-2-DG and F-Florbetapir (Amyvid) PET scan findings

- If on any of the following medications, must be on a stable dose for 60 days or
greater: Rivastigmine, Donepezil, Memantine, Glantamine, Tacrine.

Exclusion Criteria:

- Current or past history of any oncologic disease mitigating low dose whole brain RT

- Evidence of substance abuse (Alcohol/or other drugs or dependences during previous 12
months (DSM-V criteria)

- Clinically or radiographically significant evidence of stroke

- Evidence of subdural hygromas or subdural hematomas

- Active or recent (defined as within 3 months of screening) cerebral infection or
hemorrhage

- Any current conditions that may lead to the subject being in an immuno-compromised
state

- Any previous history of cranial radiation

- History of seizure activity

- History of Hydrocephalus

- Evidence of active dermatological skin disease of the scalp (except Actinic
Keratosis)

- Evidence of clinically significant major depressive disorder identified in a
psychological diagnostic interview according to the criteria of the Diagnostic and
Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)

- Evidence of psychotic disorder or psychotic episode or bipolar affective disorder
identified in a psychological diagnostic interview according to the criteria of the
Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)

- Evidence of active suicidal or homicidal ideation according to psychological
diagnostic interview

- Currently receiving other experimental treatments

- Currently requiring full-time institutional care
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02769000      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740